Increasing Reoperations and Failures With Increasing BMI in Patients Undergoing 2-Stage Exchange for Infected Total
Yehuda E Kerbel1, Gregory J Kirchner2, Ariana T Meltzer-Bruhn1
1Dept of Orthopaedic Surgery, University of Pennsylvania, Philadelphia, PA.
Background:
While morbid obesity is associated with increased infection after total hip arthroplasty, little is known on the outcomes after 2-stage reimplantation for prosthetic joint infection (PJI) in this population. The purpose of this study is to evaluate the impact of morbid obesity (body mass index>40 kg/m2) on reinfection, postoperative complications, readmissions, and reoperations.
Methods:
We conducted a retrospective review of 107 patients undergoing first time 2-stage reimplantation for PJI from 2013 to 2019. 18 patients (50% women) with body mass index>40 kg/m2 were identified. To minimize confounders, three propensity score matched cohorts were created, yielding 16 nonobese (<30 kg/m2), 16 obese (30-39.9 kg/m2), and 18 morbidly obese (>40 kg/m2) patients. Outcomes were compared using chi-square or Fisher's exact tests. All patients had minimum 12-month follow-up, with mean follow-up of 36.3, 30.1, and 40.0 months in the nonobese, obese, and morbidly obese cohorts, respectively.
Results:
Compared with nonobese patients, morbidly obese patients had a higher rate of reinfection (0% vs 33%, P = .020 and higher likelihood of length of stay>4 days (19% vs 61%, P = .012). In addition, compared with nonobese and obese patients, morbidly obese patients had higher rate of return to the operating room for any reason (13% vs 19% vs 50%, respectively, P = .020). No differences between cohorts were found regarding complications, death, or revision surgery.
Conclusion:
Morbidly obese patients have significantly increased risk of reinfection and reoperation after 2-stage reimplantation for PJI when compared with obese and nonobese patients. These data can be used to counsel morbidly obese patients contemplating total hip arthroplasty and supports the notion of deferring arthroplasty in this population pending optimization.
Insights
Morbidly obese patients face higher risks of reinfection and reoperation after two-stage prosthetic joint infection (PJI) reimplantation. This highlights the need for pre-operative optimization in this patient group undergoing hip arthroplasty.
Area of Science:
- Orthopedic surgery
- Infectious disease
- Obesity research
Background:
- Morbid obesity is linked to higher infection rates after total hip arthroplasty.
- Limited data exists on outcomes of two-stage reimplantation for prosthetic joint infection (PJI) in morbidly obese patients.
Purpose of the Study:
- To evaluate the impact of morbid obesity (BMI > 40 kg/m2) on reinfection, complications, readmissions, and reoperations after two-stage hip PJI reimplantation.
Main Methods:
- Retrospective review of 107 patients undergoing first-time two-stage PJI reimplantation (2013-2019).
- Propensity score matching created three cohorts: nonobese (<30 kg/m2), obese (30-39.9 kg/m2), and morbidly obese (>40 kg/m2).
- Outcomes compared using chi-square or Fisher's exact tests with minimum 12-month follow-up.
Main Results:
- Morbidly obese patients had higher reinfection rates (33% vs 0% in nonobese, P=.020) and longer hospital stays (>4 days, 61% vs 19%, P=.012).
- Morbidly obese patients showed increased return to OR rates (50% vs 13-19%, P=.020).
- No significant differences noted in overall complications, mortality, or revision surgery rates between groups.
Conclusions:
- Morbidly obese patients experience significantly higher risks of reinfection and reoperation following two-stage PJI reimplantation.
- Findings suggest counseling morbidly obese patients on increased risks and considering delayed arthroplasty pending optimization.
- This study provides crucial data for managing PJI in morbidly obese individuals undergoing hip arthroplasty.
Related Concept Videos
Kidney Transplant II: Surgical Procedure
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Peripheral Artery Disease V: Postoperative Nursing Management


